company background image

ProPhase Labs NasdaqCM:PRPH Stock Report

Last Price


Market Cap







06 Aug, 2022


Company Financials +
PRPH fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance4/6
Financial Health5/6

PRPH Stock Overview

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States.

ProPhase Labs Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ProPhase Labs
Historical stock prices
Current Share PriceUS$11.39
52 Week HighUS$15.25
52 Week LowUS$4.76
1 Month Change-19.51%
3 Month Change61.10%
1 Year Change56.67%
3 Year Change461.53%
5 Year Change450.24%
Change since IPO2,178.00%

Recent News & Updates

Jul 26
We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Jul 21

ProPhase Labs to license two investigational cancer compounds from Global BioLife

ProPhase Labs (NASDAQ:PRPH) on Thursday said its unit had entered into a licensing agreement with Global BioLife for two inhibitors that can be used to treat multiple indications, with an initial focus on cancer. As per the deal, PRPH unit ProPhase BioPharma obtained exclusive worldwide rights to develop and commercialize the inhibitors - LB-1 and LB-2 - for the treatment of cancer, inflammatory diseases and memory-robbing diseases. PRPH said it will evaluate LB-1 as a potential co-therapy with cancer drugs Taxol, doxorubicin, topotecan and cisplatin. The company also said that its revenue and earnings for Q2 rose Y/Y and will also grow in Q3. PRPH stock was marginally lower in the first few minutes of trading.

Shareholder Returns

PRPHUS PharmaceuticalsUS Market

Return vs Industry: PRPH exceeded the US Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: PRPH exceeded the US Market which returned -12.8% over the past year.

Price Volatility

Is PRPH's price volatile compared to industry and market?
PRPH volatility
PRPH Average Weekly Movement14.1%
Pharmaceuticals Industry Average Movement11.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: PRPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: PRPH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

1989129Ted Karkus

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

ProPhase Labs Fundamentals Summary

How do ProPhase Labs's earnings and revenue compare to its market cap?
PRPH fundamental statistics
Market CapUS$178.65m
Earnings (TTM)US$17.71m
Revenue (TTM)US$111.30m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PRPH income statement (TTM)
Cost of RevenueUS$49.56m
Gross ProfitUS$61.74m
Other ExpensesUS$44.03m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 11, 2022

Earnings per share (EPS)1.13
Gross Margin55.47%
Net Profit Margin15.91%
Debt/Equity Ratio12.1%

How did PRPH perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is PRPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRPH?

Other financial metrics that can be useful for relative valuation.

PRPH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA5.7x
PEG Ratio-0.1x

Price to Earnings Ratio vs Peers

How does PRPH's PE Ratio compare to its peers?

PRPH PE Ratio vs Peers
The above table shows the PE ratio for PRPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average16.8x
MRMD MariMed
JUSH.F Jushi Holdings
SLGL Sol-Gel Technologies
ELTP Elite Pharmaceuticals
PRPH ProPhase Labs

Price-To-Earnings vs Peers: PRPH is good value based on its Price-To-Earnings Ratio (10.1x) compared to the peer average (16.8x).

Price to Earnings Ratio vs Industry

How does PRPH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Earnings vs Industry: PRPH is good value based on its Price-To-Earnings Ratio (10.1x) compared to the US Pharmaceuticals industry average (19.3x)

Price to Earnings Ratio vs Fair Ratio

What is PRPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.1x
Fair PE Ratio7.2x

Price-To-Earnings vs Fair Ratio: PRPH is expensive based on its Price-To-Earnings Ratio (10.1x) compared to the estimated Fair Price-To-Earnings Ratio (7.2x).

Share Price vs Fair Value

What is the Fair Price of PRPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PRPH ($11.39) is trading below our estimate of fair value ($66.24)

Significantly Below Fair Value: PRPH is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Future Growth

How is ProPhase Labs forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRPH's earnings are forecast to decline over the next 3 years (-67.9% per year).

Earnings vs Market: PRPH's earnings are forecast to decline over the next 3 years (-67.9% per year).

High Growth Earnings: PRPH's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PRPH's revenue is expected to decline over the next 3 years (-17% per year).

High Growth Revenue: PRPH's revenue is forecast to decline over the next 3 years (-17% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PRPH's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has ProPhase Labs performed over the past 5 years?

Past Performance Score


Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PRPH has high quality earnings.

Growing Profit Margin: PRPH became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: PRPH has become profitable over the past 5 years, growing earnings by 42.9% per year.

Accelerating Growth: PRPH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PRPH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).

Return on Equity

High ROE: PRPH's Return on Equity (26.7%) is considered high.

Discover strong past performing companies

Financial Health

How is ProPhase Labs's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PRPH's short term assets ($72.6M) exceed its short term liabilities ($19.8M).

Long Term Liabilities: PRPH's short term assets ($72.6M) exceed its long term liabilities ($13.5M).

Debt to Equity History and Analysis

Debt Level: PRPH has more cash than its total debt.

Reducing Debt: Insufficient data to determine if PRPH's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: PRPH's debt is well covered by operating cash flow (181.7%).

Interest Coverage: PRPH's interest payments on its debt are well covered by EBIT (73.4x coverage).

Balance Sheet

Discover healthy companies


What is ProPhase Labs's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: PRPH's dividend (2.63%) is higher than the bottom 25% of dividend payers in the US market (1.52%).

High Dividend: PRPH's dividend (2.63%) is low compared to the top 25% of dividend payers in the US market (4.09%).

Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, PRPH has been paying a dividend for less than 10 years.

Growing Dividend: PRPH's dividend payments have increased, but the company has only paid a dividend for 3 years.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (35.8%), PRPH's dividend payments are well covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ted Karkus (63 yo)





Mr. Ted William Karkus has served as the Chief Executive Officer of ProPhase Labs, Inc. since June 2009. Mr. Karkus founded 2001 Forrester Financial LLC and served as its Managing Member. He is a Managemen...

CEO Compensation Analysis

Compensation vs Market: Ted's total compensation ($USD941.40K) is below average for companies of similar size in the US market ($USD1.67M).

Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: PRPH's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

Experienced Board: PRPH's board of directors are seasoned and experienced ( 10.2 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.

Top Shareholders

Company Information

ProPhase Labs, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: ProPhase Labs, Inc.
  • Ticker: PRPH
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$178.653m
  • Shares outstanding: 15.69m
  • Website:

Number of Employees


  • ProPhase Labs, Inc.
  • 711 Stewart Avenue
  • Suite 200
  • Garden City
  • New York
  • 11530
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.